An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is an extension trial of 0881A3-312-EU and is designed to provide information on the safety and efficacy of etanercept in patients with ankylosing spondylitis for up to 3 additional years.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Completed study 0881A3-312-EU

• Agreeable to utilize medically acceptable form of contraception

• Able to reconstitute and self-inject or have a designee

Exclusion Criteria:

• Withdrawn from study 0881A3-312-EU

• Abnormal hematology or chemistry profiles

• Clinically relevant medical conditions including: congestive heart failure, multiple sclerosis or other central demyelinating diseases, blood dyscrasias, cancer or serious infection